For details on clinical results with TASIGNA® (nilotinib) capsules for newly diagnosed patients with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), see the information below.
If you are already taking another medication for Ph+ CML-CP, learn why your doctor may recommend switching to TASIGNA. See reasons to switch.
A class of prescription medications called tyrosine kinase inhibitors (TKIs) has helped transform Ph+ CML-CP from a type of leukemia that was life-threatening into a manageable disease that more people are living with.
TASIGNA is a TKI that has treated approximately 28,000 people in the United States with Ph+ CML-CP since its approval in 2007.
While some people talk about Ph+ CML-CP as a “good cancer,” in reality there’s no such thing. That’s why it’s important to make sure your blood is getting the treatment—and the attention—it deserves.
Among 2nd-generation TKIs approved for Ph+ CML-CP:
- Only TASIGNA has 10 years of clinical trial data among newly diagnosed patients
- Only TASIGNA has 10 years of data tracking treatment milestones among newly diagnosed patients
Treatment milestones include:
- Early molecular response rates at 3 months
- Major molecular response (MMR) rates at 1 year
- Deep molecular response (DMR) rates by 5 years
- DMR rates by 10 years
You’ve just been diagnosed, is TASIGNA right for you?
When you’re diagnosed with Ph+ CML-CP, it can be difficult to know where to start. This Doctor Discussion Guide can help with questions and conversation starters to explore if TASIGNA is the right choice as you begin your treatment journey.
Early molecular response is a milestone, which more patients reached with TASIGNA than with GLEEVEC® (imatinib).
TASIGNA patients in chronic phase had fewer progressions
Importantly, no patients who achieved MR4.5 progressed from chronic phase to accelerated phase or blast phase at the time of the analysis. In the clinical trial, 2 patients who received TASIGNA progressed to either accelerated phase or blast crisis while 12 patients who received GLEEVEC progressed to either accelerated phase or blast crisis.
Common side effects
In clinical trials with TASIGNA, the most common side effects in adults included:
- Muscle and joint pain
- Runny or stuffy nose, sneezing, sore throat
- Night sweats
Be sure to review information about the serious and most common side effects of TASIGNA. Learn more